



# **Merseyside Inter Agency Drug Misuse Database**

**April - June 2007**

**Wirral DAAT**

**Quarter 1 2007/08**

**Esther Shepherd, Martin Chandler,  
Jim McVeigh**

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler  
IAD Manager  
Centre for Public Health  
Faculty of Health & Applied Social Sciences  
Liverpool John Moores University  
Castle House  
North Street  
L3 2AY

(0151) 231 4531

[m.chandler@ljmu.ac.uk](mailto:m.chandler@ljmu.ac.uk)

Esther Shepherd

IAD Researcher

(0151) 231 4521

[e.shepherd@ljmu.ac.uk](mailto:e.shepherd@ljmu.ac.uk)

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

# Contents

	<b><u>Page</u></b>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>3</b>
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Probation</b>	<b>4</b>
Table 3: Probation clients by Gender and Age Group	
Table 4: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Syringe Exchange Services</b>	<b>5</b>
<b>Agency</b>	
Table 5: Individuals by Gender	
Table 6: Individuals by Gender: Steroid Users omitted	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 11: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 12: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
<b>Pharmacy</b>	<b>9</b>
Table 13: Individuals by Gender	
Table 14: Individuals by Age Group	
<b>Combined</b>	<b>10</b>
Table 15: Individuals in Syringe Exchange, by Gender	
Table 16: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 17: Individuals in Syringe Exchange, by Age Group	
Table 18: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 19: Total Syringes Provided	

## **National Drug Treatment Monitoring System (NDTMS) 12**

Table 20: Individuals in contact with Treatment Services, by Gender

Table 21: Individuals in contact with Treatment Services, by Age Group

Table 22: Ethnicity of Individuals in Contact with Treatment Services

Table 23: Individuals in contact with Treatment Services, by Main Drug of Use

Table 24: Activity of Treatment Services, by Agency

## **Connexions 15**

Table 25: Individuals in Contact with Connexions, by Gender

Table 26: Individuals in Contact with Connexions, by Age

Table 27: Individuals in Contact with Connexions by Drug/Alcohol Problem

## **Combined Datasets 16**

Table 28: Total Problem Drug Users reported to the IAD, by Gender and Age Group

## **Cross Matched Datasets 17**

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided from Q2 for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

## ARREST REFERRAL (AR)

Quarter 1 (2007/08)

### Introduction

Data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

**Table 1: Individuals assessed, by Gender & Age Group**

Gender	n	%
Male	78	82.1
Female	17	17.9
Age Group		
Under 18	0	0
18-19	8	8.4
20-24	22	23.2
25-29	15	15.8
30-34	14	14.7
35-39	17	17.9
40-44	15	15.8
45+	4	4.2
<b>Total</b>	<b>95</b>	<b>100</b>

**Table 2: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly
Amphetamines	1	2
Benzodiazepines	3	2
Cannabis	25	9
Crack	21	15
Cocaine	6	26
Methamphetamines	0	1
Heroin	35	6
Methadone	12	0
Other Drug	1	0

Table 2 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Arrest Referral data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

**PROBATION****Quarter 1 (2007/08)****Introduction**

Data are provided by Merseyside Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS. Probation figures are based on DAAT of Residence, NOT DAAT of contact as with other datasets.

Note: Probation substance use data are based on frequency of use. For clarity, we will only be reporting drugs that are reported as being used daily, or weekly.

**Table 3: Probation Clients by Gender and Age Group**

Gender	n	%
Male	136	83.4
Female	27	16.6
Age Group		
Under 18	0	0
18-19	15	9.2
20-24	32	19.6
25-29	24	14.7
30-34	27	16.6
35-39	38	23.3
40-44	14	8.6
45+	13	8.0
<b>Total</b>	<b>163</b>	<b>100</b>

**Table 4: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly
Amphetamines	0	1
Benzodiazepines	3	0
Cannabis	48	49
Crack	13	30
Cocaine	1	11
Ecstasy	0	4
Heroin	37	25
Methadone	19	0
Other Opiate	0	1
Misused Prescribed	1	0
Hallucinogens	0	1

No totals are given in Table 4 as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

## SYRINGE EXCHANGE SERVICES

Quarter 1 (2007/08)

### Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

### AGENCY SYRINGE EXCHANGE

**Table 5: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	129	93.5
Female	9	6.5
<i>Total</i>	<i>138</i>	<i>100</i>
<b>All Clients</b>		
Male	349	93.1
Female	26	6.9
<i>Total</i>	<i>375</i>	<i>100</i>

**Table 6: Individuals by Gender: Steroids Users omitted**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	106	92.2
Female	9	7.8
<i>Total</i>	<i>115</i>	<i>100</i>
<b>All Clients</b>		
Male	206	89.2
Female	25	10.8
<i>Total</i>	<i>231</i>	<i>100</i>

Table 7: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	2.2	4	1.1
18-19	7	5.1	17	4.5
20-24	23	16.7	63	16.8
25-29	26	18.8	53	14.1
30-34	22	15.9	57	15.2
35-39	35	25.4	86	22.9
40-44	9	6.5	54	14.4
45+	13	9.4	41	10.9
<b>Total</b>	<b>138</b>	<b>100</b>	<b>375</b>	<b>100</b>

Table 8: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.7	2	0.9
18-19	2	1.7	3	1.3
20-24	15	13.0	18	7.8
25-29	22	19.1	27	11.7
30-34	20	17.4	38	16.5
35-39	33	28.7	72	31.2
40-44	9	7.8	37	16.0
45+	12	10.4	34	14.7
<b>Total</b>	<b>115</b>	<b>100</b>	<b>231</b>	<b>100</b>

Table 9: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	3	0.9	1	3.8
18-19	17	4.9	0	0
20-24	63	18.1	0	0
25-29	51	14.6	2	7.7
30-34	51	14.6	6	23.1
35-39	79	22.6	7	26.9
40-44	49	14.0	5	19.2
45+	36	10.3	5	19.2
<b>Total</b>	<b>349</b>	<b>100</b>	<b>26</b>	<b>100</b>

Table 10: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	1	0.5	1	4.0
18-19	3	1.5	0	0
20-24	18	8.7	0	0
25-29	25	12.1	2	8.0
30-34	32	15.5	6	24.0
35-39	66	32.0	6	24.0
40-44	32	15.5	5	20.0
45+	29	14.1	5	20.0
<b>Total</b>	<b>206</b>	<b>100</b>	<b>25</b>	<b>100</b>

Table 11: Main Drug of Use for Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	7	2.0	3	11.5
Cocaine (incl. Crack)	10	2.9	2	7.7
Heroin	121	34.7	13	50.0
Methadone	9	2.6	2	7.7
Steroids	143	41.0	1	3.8
Other*	10	2.9	0	0
Unknown	49	14.0	5	19.2
<b>Total</b>	<b>349</b>	<b>100</b>	<b>26</b>	<b>100</b>

\*'Other' contains drugs Morphine, DF118, Temazepam and Temgesic.

Table 12: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Cocaine (incl. Crack)		Heroin		Methadone		Steroids		Other		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0	0	0	0	0	1	25.0	2	50.0	0	0	1	25.0
18-19	0	0	0	0	0	0	0	0	14	82.4	0	0	3	17.6
20-24	0	0	0	0	3	4.8	0	0	45	71.4	2	3.2	13	20.6
25-29	2	3.8	0	0	13	24.5	0	0	26	49.1	1	1.9	11	20.8
30-34	3	5.3	4	7.1	23	40.4	1	1.8	19	33.3	1	1.8	6	10.5
35-39	1	1.2	6	7.0	47	54.7	4	4.7	14	16.3	4	4.7	10	11.6
40-44	4	7.4	2	3.7	24	44.4	0	0	17	31.5	1	1.9	6	11.1
45+	0	0	0	0	24	58.5	5	12.2	7	17.1	1	2.4	4	9.8
<b>Total</b>	<b>10</b>	<b>2.7</b>	<b>12</b>	<b>3.2</b>	<b>134</b>	<b>35.7</b>	<b>11</b>	<b>2.9</b>	<b>144</b>	<b>38.4</b>	<b>10</b>	<b>2.7</b>	<b>54</b>	<b>14.4</b>

Percentages are by row, not column

## PHARMACY SYRINGE EXCHANGE

**Table 13: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	59	83.1
Female	12	16.9
<i>Total</i>	<i>71</i>	<i>100</i>
<b>All Clients</b>		
Male	152	83.1
Female	31	16.9
<i>Total</i>	<i>183</i>	<i>100</i>

**Table 14: Individuals by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	8	11.3	13	7.1
25-29	13	18.3	21	11.5
30-34	12	16.9	33	18.0
35-39	16	22.5	47	25.7
40-44	18	25.4	44	24.0
45+	4	5.6	25	13.7
<i>Total</i>	<i>71</i>	<i>100</i>	<i>183</i>	<i>100</i>

## COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

**Table 15: Individuals in Syringe Exchange, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	184	89.8
Female	21	10.2
<i>Total</i>	<i>205</i>	<i>100</i>
<b>All Clients</b>		
Male	468	89.8
Female	53	10.2
<i>Total</i>	<i>521</i>	<i>100</i>

**Table 16: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	161	88.5
Female	21	11.5
<i>Total</i>	<i>182</i>	<i>100</i>
<b>All Clients</b>		
Male	325	86.2
Female	52	13.8
<i>Total</i>	<i>377</i>	<i>100</i>

**Table 17: Individuals in Syringe Exchange, by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	3	1.5	4	0.8
18-19	7	3.4	17	3.3
20-24	30	14.6	73	14.0
25-29	38	18.5	71	13.6
30-34	34	16.6	85	16.3
35-39	49	23.9	116	22.3
40-44	27	13.2	91	17.5
45+	17	8.3	64	12.3
<i>Total</i>	<i>205</i>	<i>100</i>	<i>521</i>	<i>100</i>

**Table 18: Individuals in Syringe Exchange by Age Group: Steroid Users omitted**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.1	2	0.5
18-19	2	1.1	3	0.8
20-24	22	12.1	28	7.4
25-29	34	18.7	45	11.9
30-34	32	17.6	66	17.5
35-39	47	25.8	102	27.1
40-44	27	14.8	74	19.6
45+	16	8.8	57	15.1
<b>Total</b>	<b>182</b>	<b>100</b>	<b>377</b>	<b>100</b>

**Table 19: Total Syringes Provided**

	Agency	Pharmacy	Total (Q)
Barrels	26014	14016	40030

**NB:** Total Syringes include exchanges by non-attributable individuals.

## National Drug Treatment Monitoring System (NDTMS)

Quarter 1 (2007/08)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 20: Individuals in Contact with Treatment Services, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	177	74.1
Female	62	25.9
<i>Total</i>	<i>239</i>	<i>100</i>
<b>All Clients</b>		
Male	1914	72.8
Female	714	27.2
<i>Total</i>	<i>2628</i>	<i>100</i>

**Table 21: Individuals in Contact with Treatment Services, by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	12	5.0	56	2.1
18-19	16	6.7	71	2.7
20-24	33	13.8	151	5.8
25-29	25	10.5	213	8.1
30-34	40	16.7	379	14.4
35-39	58	24.3	721	27.4
40-44	41	17.2	658	25.0
45+	14	5.9	379	14.4
<i>Total</i>	<i>239</i>	<i>100</i>	<i>2628</i>	<i>100</i>

Table 22: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	235	98.3	2594	98.7
White Irish	0	0	5	0.2
Other White	0	0	3	0.1
White & Black Caribbean	0	0	3	0.1
White & Black African	1	0.4	4	0.2
Other Mixed	1	0.4	5	0.2
Indian	0	0	1	<0.1
Pakistani	0	0	1	<0.1
Bangladeshi	0	0	1	<0.1
Other Asian	1	0.4	2	0.1
African	0	0	2	0.1
Other Black	0	0	1	<0.1
Other	0	0	1	<0.1
Unknown	1	0.4	5	0.2
<b>Total</b>	<b>239</b>	<b>100</b>	<b>2628</b>	<b>100</b>

Table 23: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	97	40.6	1827	69.5
Methadone	23	9.6	85	3.2
Other Opiates	5	2.1	97	3.7
Benzodiazepine	1	0.4	15	0.6
Amphetamines	5	2.1	55	2.1
Cocaine	41	17.2	191	7.3
Crack	19	8.0	115	4.4
Hallucinogens	3	1.3	5	0.2
Ecstasy	4	1.7	20	0.8
Cannabis	36	15.1	204	7.8
Prescription Drugs	5	2.1	6	0.2
Unknown	0	0	8	0.3
<b>Total</b>	<b>239</b>	<b>100</b>	<b>2628</b>	<b>100</b>

Table 24: Activity of Treatment Services, by Agency

Agency	All Clients	
	n	%
Arch-Argyle HC	874	33.3
Arch Ball Road	34	1.3
Wirral Drug Service	1496	56.9
Phoenix House Wirral	36	1.4
Arch Bail Support	55	2.1
Pier	15	0.6
Response	58	2.2
Wirral YOT	56	2.1
16-19s Team	4	0.2
<b>Total</b>	<b>2628</b>	<b>100</b>

**CONNEXIONS**

Quarter 1 (2007/08)

**Background**

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 25: Individuals in Contact with Connexions, by Gender**

Gender	n	%
Male	79	69.9
Female	34	30.1
<b>Total</b>	<b>113</b>	<b>100</b>

**Table 26: Individuals in Contact with Connexions, by Age**

Age Group	n	%
16	35	31.0
17	33	29.2
18	28	24.8
19	17	15.0
<b>Total</b>	<b>113</b>	<b>100</b>

**Table 27: Individuals in Contact with Connexions by Drug/Alcohol Problem**

Substance	n	%
Alcohol/Other*	46	40.7
Drugs	67	59.3
<b>Total</b>	<b>113</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 1 (2007/08)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

**Table 28: Total Problem Drug Users reported to the IAD, by Gender and Age Group**

Gender	n	%
Male	2405	75.4
Female	783	24.6
Age Group		
Under 18	172	5.4
18-19	151	4.7
20-24	382	12.0
25-29	552	17.3
30-34	694	21.8
35-39	682	21.4
40-44	361	11.3
45+	194	6.1
<b>Total</b>	<b>3188</b>	<b>100</b>

## CROSS-MATCHED DATASETS


Quarter 1 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

**Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets**



**Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets**

